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Abstract
Objective: To assess the relationship of the grade of unruptured and untreated
Brain Arteriovenous Malformations (AVMs), with the risk of subsequent stroke
and death during follow-up. Methods: This prospective study was drawn from
a cohort of adult patients with unruptured AVMs, who participated in the con-
servative treatment arm (medical management only for headache or seizures) of
the randomized clinical trial of unruptured brain AVMs (ARUBA study). The
grade of AVMs (Spetzler–Martin scale) was dichotomized into categories:
AVMs of grades I and II were considered low grade; AVMs of grades III and
IV were considered high grade. There were no grade V AVM patients in
ARUBA. The primary outcome was symptomatic stroke (hemorrhagic or
ischemic – documented by imaging) or death. Results: The conservative treat-
ment group had 123 patients (“as treated” analysis). 71 (57.7%) had lesions
characterized for this analysis as low-grade lesions and 52 (42.2%) as high
grade. From the total of 10 (8.13%) primary outcomes, three occurred (4.22%)
in low-grade AVMs and seven (13.46%) in high-grade AVMs (P = 0.0942).
Interpretation: Statistical analysis of the cohort of patients with unruptured
and untreated AVMs from ARUBA study showed that the graduation categories
(Spetzler–Martin grades) were not associated with the outcome of subsequent
stroke or death.
Introduction
Brain Arteriovenous Malformations (AVMs) are complex
lesions with potential to cause hemorrhagic and nonhem-
orrhagic events followed by devastating neurological defi-
cits, long-term disability, and death.1–8 Annual ICH rates
in untreated AVMs range from about 2 to 4%.2,9,10 These
rates may vary according to several AVM characteristics,
such as location, venous drainage, lesion size, presence of
associated aneurysms, or history of previous bleeding.11,12
It has long been hypothesized that unruptured and
untreated high-grade AVMs may have a higher risk of
subsequent bleeding than those of low-grade lesions.
The ARUBA study13 was registered in the database
“www.clinicaltrials.gov,” under the number NCT00389181.
Participation in the trial was approved by institutional
committees or ethics committees in the 39 international
institutions involved, and all participants gave informed
consent prior to randomization13. The study received sup-
port, monitoring and funding from NIH and NINDS
(National Institutes of Health, National Institute of Neuro-
logical Disorders and Stroke, respectively).13 All outcome
events were adjudicated by a 4-member panel of interna-
tionally recognized clinicians experienced with AVM diag-
nosis and management. The ARUBA data quality was
reviewed by an NINDS-appointed Data and Safety Moni-
toring Board (DSMB). Randomization was halted by the
DSMB after 226 patients had been entered, with 223 of
them participating in the trial long enough for outcome
assessments to be made.13
The results of a randomized clinical trial involving brain
AVMs discovered without having bled (unruptured) –
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ARUBA, offers an excellent opportunity for further studies
on the risks of bleeding and intervention in unruptured
AVMs. The purpose of this study was to use the published
trial data (from ARUBA) to assess the relationship between
the grades (according to the Spetzler and Martin14 scale) of
unruptured and untreated brain AVMs and the risk of sub-
sequent hemorrhagic stroke and death in the natural his-
tory of these lesions.
Methods
The ARUBA trial13 database consisted of two prospective
randomized arms of AVM patients, one to receive conser-
vative treatment alone (observation only, without inter-
vention, medical therapy for headache or seizures) and
the other to receive the same medical therapy but with
intervention intended to eradicate the AVM. All patients
had the AVMs characterized in relation to its angioarchi-
tecture and stratified according to the Spetzler–Martin14
classification, including lesion size, location in eloquent
brain area and type of venous drainage as some of the
evaluated parameters. The combined primary outcome
was the occurrence of an event of symptomatic stroke
(hemorrhagic or ischemic) or death from any cause in
the evaluated patients. Intracranial hemorrhage (ICH)
was characterized as an episode of focal neurological defi-
cit, seizure or new onset headache, associated with hem-
orrhage imaging findings. A stroke of death outcome
ended formal participation of the individual patient in
the trial.13 During ARUBA study, Kaplan–Meier curves of
time from randomization to outcome event documented
the course for those “as randomized” and a separate anal-
ysis was made for those “as treated.”13
The analysis of this article used data from the conserva-
tive treatment arm of ARUBA.13 The influence of the grades
of brain AVMs, established by the classification of Spetzler
and Martin,14 on the risk of hemorrhagic stroke or death
during the natural history of these lesions, was examined.
The ARUBA study13 provided data from its “as trea-
ted” analysis for the group receiving conservative treat-
ment (unruptured and untreated AVMs). This group of
patients had 125 individuals.13 The data show the patients
and their respective AVMs stratified according to the
Spetzler–Martin classification grades and identify the
number of primary outcomes that occurred in each of
these grades.
Randomization to ARUBA was permitted based on
Magnetic Resonance Imaging (MRI) alone. Nevertheless,
all but two patients also underwent catheter angiography.
These two patients imaged by MRI alone (catheter
angiography not available) had been randomized to the
conservative arm, and the Spetzler–Martin grade was not
available for them. Thus, the final sample of this study
(“as treated” analysis) was composed of 123 patients with
unruptured and untreated AVMs originated from ARUBA
conservative treatment arm (Table 1).
For this study, statistical analysis was made of data
available from ARUBA study.13 Using the AVM stratifica-
tion according to the Spetzler–Martin scale, the lesion
grade variable was dichotomized into categories: AVMs of
grades I and II of the Spetzler–Martin classification were
considered low-grade AVMs; Spetzler–Martin grades III,
IV and V AVMs were considered high-grade AVMs. In
the available data there were no records of Spetzler–Mar-
tin grade V AVMs. Outcome variables of symptomatic
stroke (hemorrhagic or ischemic) or death were also
dichotomized according to their occurrence (yes, positive;
no, negative). In a first step, data regarding to AVMs
stratification in the Spetzler–Martin classification and the
respective number of patients in each grade of this scale
were obtained. Next, the number of patients in each
AVM high- and low-grade category was calculated as fol-
lows: the number of patients whose lesions were classified
in Spetzler–Martin grades I and II was summed to consti-
tute the category of low-grade AVMs; the number of
patients whose lesions were classified in Spetzler–Martin
grades III and IV was summed to constitute the category
of high-grade AVMs. In a second step, data regarding to
the outcome over the follow-up period were extracted.
Statistical analysis was performed considering the cate-
gorical variables of high and low grade and correlating
them with the occurrence of the outcome (stroke or
death), in each of these graduation categories. According
to the study hypothesis, the group of low-grade AVMs
(Spetzler–Martin I and II) would represent patients not
exposed to a higher risk of hemorrhagic stroke or death;
the group of high-grade AVMs (Spetzler–Martin III, IV
and V) would represent patients exposed to a higher risk
of hemorrhagic stroke or death. Data analysis was per-
formed using Fisher’s exact test, conducted through
Table 1. The Spetzler–Martin classification and number of patients








Grade I AVMs 37 2
Grade II AVMs 34 1
Grade III AVMs 34 3
Grade IV AVMs 18 4
Grade V AVMs 0 0
Source: prepared by the authors.
AVMs, Brain Arteriovenous Malformations.
1Total of 123 patients in ARUBA database who had angiographic data
available to be classified according to the Spetzler–Martin system.
2Total of 10 outcomes occurred during the follow-up period.
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GraphPad Instat statistical software (version 3 for Win-
dows, GraphPad Software, San Diego, CA; http://www.gra
phpad.com). The P < 0.05 was used to consider the sta-
tistically significant results and 95% confidence intervals
(CI) were used to display the results found.
Results
During the ARUBA study period, 226 patients were
recruited.13 However, the final sample of the population
included in ARUBA was 223 patients, which were random-
ized with adequate follow-up data.13 From this total, accord-
ing to the study’s original randomization, 114 were allocated
to the prospective arm that received interventional treat-
ment, and 109 were allocated to the conservative treatment
arm. During ARUBA, some patients chose to change their
treatment assignment from conservative to intervention or
the opposite. The outcomes for these patients were reported
“as treated” analysis, that is, as the treatment groups were
actually composed. Therefore, drawing on the “as treated”
cohort, the data analyzed in this study was formed by these
125 individuals with unruptured and untreated AVMs.
However, of 125 patients in the conservative treatment arm
of ARUBA database, the Spetzler–Martin scale grade was not
available for two patients (catheter angiography not available
at the time of inclusion in the study).13
Of the total of 123 patients with unruptured and
untreated lesions stratified into grades of the Spetzler–Mar-
tin scale, 71 (57.7%) AVMs were considered of low grade (I
and II) and 52 (42.2%) AVMs were considered of high
grade (III and IV). Primary outcome (symptomatic stroke
or death from any cause) occurred in 10 (8.13%) of 123
patients randomized to receive conservative treatment.
From this total of primary outcomes, among AVMs consid-
ered of low grade, there were three (4.22%) events of symp-
tomatic stroke or death; among AVMs considered to be of
high grade there were seven (13.46%) events of symp-
tomatic stroke or death (Table 2).
The correlation of primary outcome occurrences between
the two AVM Spetzler–Martin grades categories showed a p
value of 0.0942 (RR = 0.319; 95% CI: 0.085–1.157), a result
considered not statistically significant (Fig. 1). This finding
indicated that, in this cohort of patients with unruptured
and untreated AVMs, the grading categories formed by the
Spetzler–Martin classification were not associated with sub-
sequent hemorrhagic stroke or death.
Discussion
The complexity of brain AVMs makes them a heteroge-
neous group of lesions, with several factors assumed pos-
sible to affect the risk of rupture with subsequent
hemorrhagic stroke.9,15 Since brain AVMs can be associ-
ated with a potentially severe natural history,16 determin-
ing the rupture risk is crucial to establish the appropriate
treatment.5,17
Cohort studies and meta-analyses have improved the
ability to predict the hemorrhagic event in AVMs.18 Sev-
eral descriptions of angioarchitectural features of AVMs
that would be associated with an increased hemorrhagic
risk have been reported,18 both as initial hemorrhagic
presentation19–22 and during the natural course of AVMs
(subsequent, future hemorrhages).15,23,24
The ARUBA study13 provided the first results of a ran-
domized trial involving unruptured brain AVMs. These
results triggered a detailed examination of the relationship
between Spetzler–Martin grades and the hemorrhagic out-
come and clinical severity of these events. The AVM classi-
fication proposed by Spetzler and Martin14 allows to assess
the complexity of these lesions and to estimate the risk
related to surgical treatment. This classification system is
currently the most widely used, due to its ease of applica-
tion and its correlation with the prognosis.23 The Spet-
zler–Martin system relates morphology (size and venous
drainage of the AVM) and localization (neurological elo-
quence of the brain adjacent to the AVM) in order to
grade the lesion and predict its surgical risk. The results
from the present analysis indicates that the evaluated
unruptured and untreated AVMs failed to show an associ-
ation between the original grades of Spetzler–Martin scale
and the occurrence of subsequent hemorrhagic stroke.
Although not from a randomized sample, similar failure
was reported by Padilla-Vazquez et al.25 and Tasic et al.26
The risks and outcomes related to the natural history
of high-grade AVMs (Spetzler–Martin grades IV and V)
are of special interest, particularly considering the high
risk of treatment of these lesions.27 A prospective study
investigating the natural history of 63 untreated high-
grade AVMs found that 23 patients (37%) suffered subse-
quent bleeding, resulting in an annual mean hemorrhage
rate of 3.3% for untreated high-grade lesions.27 Malfor-
mations classified in grades IV and V (Spetzler–Martin)
and with large sizes may have a higher prospective
Table 2. The total number of patients in AVMs grades categories






(Spetzler–Martin grades I and II)
71 3
High grade
(Spetzler–Martin grades III and IV)
52 7
Total 123 10
Source: prepared by the authors.
AVMs, brain arteriovenous malformations.
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hemorrhagic rate,24,28 but not in other studies,27,29
demonstrating that there is no consensus on this subject.
Some authors have suggested that AVMs located in deep
regions, such as the basal ganglia, the periventricular or
intraventricular space, are at increased risk of bleeding.22,30
Several locations of AVMs were associated with a higher
occurrence of hemorrhage at the initial presentation, such
as the cerebellum, brainstem, temporal lobe, insula, corpus
callosum, the basal ganglia, and ventricles.22,31 Yang et al.32
conducted a study seeking factors associated with hemor-
rhage in AVMs, observing that variables such as nonfrontal
lobar location, basal ganglia location or brainstem location
were associated with hemorrhagic presentation in brain
AVMs. Stefani et al.33 reported that deep location was a
factor significantly associated with initial hemorrhage in
AVMs, whereas Tong et al.31 verified that infratentorial
and deep location may be associated with initial hemor-
rhage in AVMs. Ellis et al.34 observed that infratentorial
location was independently associated with hemorrhagic
presentation in pediatric AVMs. A retrospective study
reported that hemorrhagic presentation was significantly
more common in deep pediatric AVMs, located in the basal
ganglia, thalamus, and brainstem.35
Consistently implicated in subsequent hemorrhage
related to AVMs would be infratentorial and deep cerebral
location.9,15 Nevertheless, according to Santos et al.,36 the
incidence of hemorrhage related to the location of AVM
nidus is controversial. Mohr and Yaghi37 stated that ence-
phalic location appears to have no influence on the size,
vascular complexity and tendency for hemorrhage of brain
AVMs. Analyzing the natural history of AVMs, several
studies did not show a relationship between location and
bleeding risk.27,38,39 Ma et al.40,41 analyzed pediatric
patients with AVMs seeking risk factors for hemorrhagic
presentation and subsequent hemorrhage (follow-up),
obtaining conflicting results.
The venous characteristics of AVMs have been widely
evaluated and implicated in the hemorrhage of these
lesions.42,43 The association between deep venous drainage
and a higher incidence of hemorrhagic presentation was
reported by several studies.19,20,22,39,44,45 Studies involving
pediatric AVM patients found that deep venous drainage
was associated with hemorrhagic presentation.34,35
The studies of Alexander et al.,5 Kubalek et al.,11 Padilla-
Vazquez et al.25 and Hernesniemi et al.15 supported previ-
ous reports that exclusively deep venous drainage in brain
AVMs is more commonly associated with bleeding than
exclusively superficial venous drainage or mixed venous
drainage. However, the studies by Ma et al.40,41 analyzed
characteristics of pediatric AVMs and showed that deep
(and exclusively deep) venous drainage was not a predictor
of hemorrhagic presentation in these lesions. The same
authors41 also found that deep venous drainage did not
affect the risk of subsequent rupture. More information is
needed to delineate the role of complex venous features
and its influence in the natural history of AVMs.5,9,23
The issue of AVMs size and its relation to hemorrhagic
risk in the natural history of these lesions has already been
analyzed by several authors, with different results.19,38,46,47
The association between size and hemorrhagic presentation,
Figure 1. Brain Arteriovenous Malformations (AVMs) Grades (Derived from the Spetzler–Martin Classification System) versus Primary Outcome.
The graph relates AVMs grades categories (composed by the Spetzler–Martin scale) with the occurrence of primary outcome. Source: adapted by
the authors from GraphPad Instat (version 3, GraphPad Software, San Diego, CA).
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especially in the group of small AVMs (<3 cm), has already
been suggested.32,48,49 In the study by Yang et al.,32 small
size was associated with hemorrhagic presentation, with a
reduction of 0.35 in the odds ratio (OR) for hemorrhagic
risk every 1 cm increase in AVM size (OR = 0.65;
P < 0.01). Fok et al.,1 Tong et al.45 and Sahlein et al.50
showed that small size was a risk factor for hemorrhagic
presentation. Ma et al.40 analyzed characteristics of AVMs
to assess hemorrhagic risk in children, concluding that a
smaller nidal size was a risk factor for initial hemorrhage.
In the study by Alexander et al.,5 AVM size was inversely
related to hemorrhagic presentation. Other authors stated
that small AVMs are associated with an increased hemor-
rhagic risk.11,17,36,51–54
Conversely, several authors did not verify a predictive
value of hemorrhage risk for AVM size, including natural
history hemorrhages.30,55 Analyzing untreated AVMs in
children, Ma et al.41 found no association between size
and risk of subsequent hemorrhage. Neither the meta-
analysis performed by Gross and Du56 nor the cohorts of
the MARS study57 (“Multicenter AVM Research Study”)
found association of size with increasing risk of AVM-
related hemorrhage. According to Morgan et al.,23 size
would be unlikely to play a significant role in relation to
the risk of subsequent hemorrhage in AVMs.
Demonstrating the disagreement regarding the role of
size in hemorrhagic risk, some authors have pointed out
that large AVMs (>3 cm) are associated with a higher risk
of subsequent bleeding.9,15,16,24,58 Brain AVMs with large
sizes may present in nonhemorrhagic forms, which could
lead to an overestimation of hemorrhage rate in small
AVMs.39 The finding that small size predicts hemorrhagic
presentation but significantly decreases the risk of future
bleeding, suggests that a significant proportion of small
unruptured AVMs remain undetected throughout life or
are not discovered until a hemorrhage occurs, possibly
not being accounted for in natural history studies.9
Beyond that, patients with small AVMs may proportion-
ally experience more episodes of hemorrhage, not because
the smaller size would indeed be a risk factor, but
through its association with previous hemorrhage.15
In contrast to this study, most similar publications are
retrospective, not population-based and certainly nor ran-
domized-based. Additionally, publications that report only
their referral cohort may be unintentionally biased by their
sample. Many previous studies have examined hemorrhagic
risk in AVMs, but most have not included the Spetzler–Mar-
tin grade as a factor that may be associated with bleeding.
This study had some limitations. In the statistical anal-
ysis of data obtained from ARUBA13, follow-up times of
patients in each category of grades from the Spetzler–
Martin scale were not included in the calculation. The
combination of the number of patients available in each
of the Spetzler–Martin14 grades, to compose the cate-
gories, may have interfered with the result. The fact that
the study had a combined outcome (death or stroke),
may have influenced analysis. Hence, the current result
should be interpreted with caution.
In conclusion, this article analyzed the relationship
between the grades of cerebral AVMs and the risk of
symptomatic stroke or death. Analysis of the cohort of
patients with unruptured and untreated AVMs from
ARUBA showed that the graduation categories (formed
by the Spetzler–Martin grades) were not associated with
the outcome of subsequent stroke or death. Our result
raises the question whether it is possible to predict which
patients will bleed based on Spetzler–Martin grade, not
demonstrated in the only randomized trial to date. This
article will contribute to the process of understanding the
influence of AVMs grades on the risk of subsequent hem-
orrhage throughout the natural history of these lesions.
We recommend that the results of this article serve as a
starting point for further investigations into hemorrhagic
risk factors in unruptured and untreated AVMs.
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